Biomarker-guided immunomodulation in septic shock: navigating controversies and therapeutic implications for Critical Care - Summary - MDSpire

Biomarker-guided immunomodulation in septic shock: navigating controversies and therapeutic implications for Critical Care

  • By

  • Yuxiu Dai

  • Hengyang Liu

  • Dingwen Xu

  • June 26, 2026

  • 0 min

Share

Objective:

To discuss the implications of sTREM-1 as a biomarker in septic shock and its challenges in clinical application.

Approach:
  • Biomarker Predictive Performance: sTREM-1 is a predictor of 90-day mortality and major adverse kidney events (MAKE) in ICU patients, comparable to complex machine learning models.
  • Cutoff Value Controversy: There is no harmonized cutoff value for sTREM-1, with proposed thresholds varying significantly across studies, complicating clinical implementation.
  • Translational Challenges: Conflicting trial data regarding TREM-1 inhibition complicates the use of sTREM-1 as a companion diagnostic.
  • Static vs. Dynamic Measurements: Current practices rely on static single-point measurements of sTREM-1, which may not reflect the dynamic nature of critical illness.
  • Generalizability Issues: The generalizability of sTREM-1 across diverse ICU populations is questioned, as elevations are not uniform across all infections or organ failures.
Key Findings:
  • sTREM-1 predicts mortality and MAKE but lacks standardized cutoff values.
  • Discrepancies in proposed thresholds pose challenges for risk assignment in clinical practice.
  • Conflicting trial data raises questions about the role of sTREM-1 in identifying patients for TREM-1 targeted therapies.
  • Static measurements of sTREM-1 may not adequately capture the evolving nature of immune dysregulation in critical illness.
  • sTREM-1 elevations vary across different ICU populations, suggesting a need for multimodal assessment.
Interpretation:

The findings highlight the need for harmonized assays, prospective trials, and integration of both static and dynamic biomarker assessments in critical care.

Limitations:
  • Lack of standardized cutoff values for sTREM-1 hampers clinical application.
  • Conflicting data regarding the efficacy of TREM-1 inhibition complicates its use as a diagnostic tool.
  • Static measurements may not reflect the dynamic changes in patient condition.
Conclusion:

sTREM-1 is a significant biomarker in septic shock, but its clinical utility is hindered by variability in measurement and interpretation.

Sources:

Original Source(s)

Related Content